Biosimilar Denosumab Matches Reference on Lumbar Spine Bone Density

This meta-analysis gives geriatric pharmacists pooled randomized evidence that denosumab biosimilars are therapeutically interchangeable for postmenopausal osteoporosis, with a minor total hip signal favoring the reference product.

denosumabbiosimilar denosumabRANKL inhibitorpostmenopausal osteoporosisbone mineral densitymeta-analysisgeriatric pharmacyimmunogenicity Geriatrics / Geriatric Pharmacy

Background Information

Biosimilar denosumab matches reference in treating osteoporosis.

Denosumab is used to manage osteoporosis in postmenopausal women, and understanding the efficacy of its biosimilar is crucial for safe, cost-effective treatment options. Both reference and biosimilar denosumab showed similar lumbar spine bone mineral density (BMD), though reference denosumab had a slight advantage in hip BMD. This study indicates biosimilar denosumab is a viable alternative to reference denosumab, but further studies are needed for long-term safety and efficacy in diverse populations. Biosimilar denosumab may be as effective as reference denosumab in postmenopausal osteoporosis.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Zainab S, Zaheer L, Sheikh AR, Khalid MS, Arshad MZ, Khatoon A, Zahra N, Ahmed E, Zakir E, Fatima E, Tariq A, Abbas K, Kanwal A, Haq UU, Khan AA, Suman S

Citation: Zainab S, Zaheer L, Sheikh AR, et al. Comparative efficacy of biosimilar denosumab and reference denosumab in treatment of postmenopausal osteoporosis: a systematic review and meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2026. doi:10.1007/s00198-026-08159-3

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →